{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T19:09:22Z","timestamp":1773428962101,"version":"3.50.1"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Alpelisib is a PIK3a inhibitor approved for the treatment of metastatic ER+ breast cancer in combination with fulvestrant. Although rash is a common side effect of this medication, we present the first case of drug reaction with eosinophilia and systemic symptoms (DRESS) upon initial exposure to alpelisib. Here we describe the clinical-pathological findings and management of our patient with alpelisib-induced life-threatening DRESS syndrome. The goal of this case report is to highlight association of alpelisib with DRESS syndrome, in clinical practice, so that alpelisib can be immediately stopped and treatment for this serious condition promptly initiated.<\/jats:p>","DOI":"10.3389\/fonc.2021.726785","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T10:04:36Z","timestamp":1629799476000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Alpelisib-Induced Drug Reaction With Eosinophilia and Systemic Symptoms: A Rare Manifestation of a Common Side Effect"],"prefix":"10.3389","volume":"11","author":[{"given":"Umair","family":"Majeed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tudor","family":"Puiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Sluzevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marites","family":"Acampora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Moreno-Aspitia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine J.","family":"Bodiford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12501","article-title":"Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): An Original Multisystem Adverse Drug Reaction. Results From the Prospective RegiSCAR Study","volume":"169","author":"Kardaun","year":"2013","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the Number of Women Living With Metastatic Breast Cancer in the United States","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive Molecular Portraits of Human Breast Tumours","volume":"490","author":"Sheth","year":"2012","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0865","article-title":"Characterization of the Novel and Specific PI3K\u03b1 Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials","volume":"13","author":"Fritsch","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3652","article-title":"FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients With HR-Positive, HER2-Negative, PIK3CA-Mutated, Advanced or Metastatic Breast Cancer","volume":"27","author":"Narayan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-Mutated, Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05726-y","article-title":"Dermatologic Adverse Events Related to the PI3K\u03b1 Inhibitor Alpelisib (BYL719) in Patients With Breast Cancer","volume":"183","author":"Wang","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.08.013","article-title":"Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Identified in the Electronic Health Record Allergy Module","volume":"7","author":"Wolfson","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-Induced Hypersensitivity Syndrome (DiHS)\/drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): An Update in 2019","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M506119200","article-title":"Phosphoinositide 3-Kinase Signaling to Akt Promotes Keratinocyte Differentiation Versus Death","volume":"280","author":"Calautti","year":"2005","journal-title":"J Biol Chem"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.198","article-title":"Drug Reaction With Eosinophilia and Systemic Symptoms: A Retrospective Study of 60 Cases","volume":"146","author":"Chen","year":"2010","journal-title":"Arch Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of Drug Rash With Eosinophilia and Systemic Symptoms Syndrome: A Morphological and Phenotypical Study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1297422","article-title":"Prediction and Management of Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS)","volume":"13","author":"Shiohara","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1270940","article-title":"Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Incidence, Pathogenesis and Management","volume":"16","author":"Shiohara","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0048","article-title":"Evaluation of Cyclosporine for the Treatment of DRESS Syndrome","volume":"156","author":"Nguyen","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.1949","article-title":"A Case of Recalcitrant DRESS Syndrome With Multiple Autoimmune Sequelae Treated With Intravenous Immunoglobulins","volume":"149","author":"Singer","year":"2013","journal-title":"JAMA Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.07.004","article-title":"Drug-Induced Hypersensitivity Syndrome With Myocardial Involvement Treated With Tofacitinib","volume":"5","author":"Damsky","year":"2019","journal-title":"JAAD Case Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2009.10.054","article-title":"Cyclophosphamide Therapy for Corticoresistant Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome in a Patient With Severe Kidney and Eye Involvement and Epstein-Barr Virus Reactivation","volume":"55","author":"Laban","year":"2010","journal-title":"Am J Kidney Dis"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.726785\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T10:04:39Z","timestamp":1629799479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.726785\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":18,"alternative-id":["10.3389\/fonc.2021.726785"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.726785","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"article-number":"726785"}}